EU5 Cervical Cancer Market Insights, Epidemiology and Market Forecasts 2016-2023 – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Cervical
Cancer-Market Insights, Epidemiology and Market Forecast – 2023 – EU5”

drug pipelines to their offering.

The therapeutic market size of Cervical Cancer in European (EU5) market
is expected to grow at a Compound Annual Growth Rate of 0.019% and reach
up to USD 109.8 million by 2023.

The global market size of prophylaxis treatment for Cervical Cancer is
expected to grow at a Compound Annual Growth Rate of 0.71% and reach up
to USD 2210.9 Million by 2023.

Cervical Cancer needs to be focused more and more because it adversely
affects younger women. It is the fourth most common cause of death among
women. Cervical Cancer occurs due to the uncontrolled growth of healthy
cells in cervix and forms cervical lesions. It spreads to other tissues
such as vagina and uterus. Cervical Cancer is caused by inheritance of
defects or mutation in genes.

Cervical cancer is also caused due to the infection by the Human
Papilloma Virus (HPV) which can infect cells on the surface of the skin
and those lining the genitals, anus, mouth and throat, but not the blood
or internal organs such as the heart or lungs.

Key Topics Covered:

  1. Report Introduction
  2. Cervical Cancer Disease Overview
  3. Diagnosis of Cervical Cancer
  4. Epidemiology and Patient Population of Cervical Cancer
  5. United Kingdom (UK)
  6. Germany (GE)
  7. Italy (IT)
  8. France (FR)
  9. Spain (SP)
  10. Treatment Landscape
  11. Treatment Algorithm
  12. Treatment by Stages
  13. Cervical Cancer Treatment Regimens
  14. Current Unmet Needs
  15. Cervical Cancer Emerging therapies Market Size
  16. Pipeline Product Analysis
  17. Cervical Cancer Therapeutics Market in Europe
  18. Cervical Cancer Prophylaxis Treatment Global
  19. Market Drivers
  20. Market Barriers
  21. Appendix

For more information about this drug pipelines report visit


Research and Markets
Laura Wood, Senior Manager
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Topics: Cervical
Cancer Drugs